Central Nervous System News and Research

RSS

RONA MS Bike Tour organized for the benefit of the Quebec Division of the MS Society a huge success

The 20th edition of the RONA MS Bike Tour, organized for the benefit of the Quebec Division of the Multiple Sclerosis Society of Canada, ended last weekend in a glow of unbelievable generosity. Together, the 1,500 cyclists raised $1,450,000, which will fund research and services for people with multiple sclerosis (MS) and their families. Participants got together in the Victoriaville area on August 22 and 23, and in the Levis region on August 29 and 30.

8 Sep 2009

Recruitment for the Phase IIa clinical trial to assess CNS 7056 sedative completed by PAION

The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces the successful completion of the Recruitment for the Phase IIa clinical trial assessing the new short-acting intravenous anesthetic/sedative CNS 7056 in patients undergoing endoscopy of the upper gastrointestinal tract.

8 Sep 2009

Regurin XL capsule for the treatment of OAB launched in UK

Regurin(R) XL (trospium chloride), a once-daily, prolonged-release capsule to treat patients with overactive bladder (OAB) has been launched in the UK. Regurin(R) XL provides rapid, significant and consistent improvements in the symptoms of OAB1 and has a reduced potential for central nervous system (CNS) side effects(2-7).

7 Sep 2009

Advisory company focused on the development of personalized medicine launched

Elixior Limited, the advisory company focused on the development and growth of innovative personalized medicine businesses, announced today its launch by the founder and former CEO of Curidium, Dr Anne Bruinvels.

7 Sep 2009

Alzheimer’s disease researcher joins UBC's European Scientific Advisory Board

United BioSource Corporation (UBC) announced this summer at ICAD 2009 that Bengt Winblad, MD, PhD has joined its European Scientific Advisory Board for CNS Clinical Trials. Professor Winblad is one of the world’s leading Alzheimer’s disease researchers and currently serves as Professor of Geriatric Medicine and Chief Physician at the Karolinska University Hospital, Huddinge, and the Karolinska Institute in Stockholm, Sweden.

5 Sep 2009

Clinical trial of Cerebroprotein Hydrolysate for Injection completes

Hard to Treat Diseases (the "Company") announced today, that its China based subsidiary Mellow Hope, has just finished (August 2009) the clinical trial of Cerebroprotein Hydrolysate for Injection (Brand name: NUTRIPROTEIN) in India.

5 Sep 2009

HTDS announces closure of Regulation D 504 offering

Hard to Treat Diseases (the "Company") (HTDS.PK) announced today that it has closed its Regulation D, Rule 504 offering and is no longer selling shares of its common stock to accredited investors.

4 Sep 2009

StemCells’ novel neuroprotective approach for treating neurodegenerative diseases

StemCells, Inc. today announced the publication of preclinical data demonstrating for the first time that transplantation of its proprietary, purified human neural stem cells delays the loss of motor function in a mouse model of infantile neuronal ceroid lipofuscinosis (NCL).

4 Sep 2009

Ten of ChemBridge's screening libraries available through CDD database

ChemBridge Corporation, a leading discovery chemistry company offering an extensive portfolio of discovery chemistry products and contract research services, has now made ten of their most popular screening libraries available to researchers via the Collaborative Drug Discovery (CDD) Public Access database.

3 Sep 2009

PTC Therapeutics collaborates with Roche for developing bioavailable small molecules

PTC Therapeutics, Inc. (PTC) today announced an exclusive research collaboration and licensing agreement with Roche for the development of orally bioavailable small molecules utilizing PTC's technology called Gene Expression Modulation by Small-molecules (GEMS(TM)).

3 Sep 2009

Consortium on Neuroscience, Ethics, Legal and Social Issues

The Center for Neurotechnology Studies at the Potomac Institute for Policy Studies is proud to announce the launch of the Capital Consortium on Neuroscience, Ethics, Legal and Social Issues (CCNELSI) on Friday September 4, 2009.

3 Sep 2009

Sepracor to be acquired by Dainippon Sumitomo Pharma for $2.6 billion

Dainippon Sumitomo Pharma Co., Ltd. (“DSP”, TSE: 4506) and Sepracor Inc. (“Sepracor”, Nasdaq: SEPR) today announced that they have entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share, followed by a merger to acquire all remaining outstanding Sepracor shares at the same price paid in the tender offer.

3 Sep 2009

NCI to announce the results of follow-up study of PharmaGap's lead drug GAP-107B8

PharmaGap Inc. (TSX-V: GAP; OTC.BB: PHRGF) ("PharmaGap" or "the Company") today announced that results are expected during September from the United States National Cancer Institute (NCI) follow-up study of the company's lead drug GAP-107B8.

2 Sep 2009

PROTECT clinical study aimed at the assessment of rolofylline effects

Despite the promising findings of the PROTECT Pilot study, the larger PROTECT trial found no difference with rolofylline versus placebo with respect of the primary and main secondary end-points of the study. Although more rolofylline patients than placebo patients experienced moderate or marked dyspnea improvement at 24 and 48 hours from randomization, this was counterbalanced by a lack of effect on persistent renal impairment. Lastly, the risk of important neurological events was increased in patients on rolofylline.

2 Sep 2009

Irbesartan drug minimizes heart failure complications in patients with atrial fibrillation

In a major international trial, researchers from McMaster University in Canada, found that the hypertension drug irbesartan reduced the risk of heart failure complications and the combination of stroke, other embolic events and transient ischemic events, also known as ministrokes, in patients with atrial fibrillation.

2 Sep 2009

Central Nervous System News and Research

RONA MS Bike Tour organized for the benefit of the Quebec Division of the MS Society a huge success

Recruitment for the Phase IIa clinical trial to assess CNS 7056 sedative completed by PAION

Regurin XL capsule for the treatment of OAB launched in UK

Advisory company focused on the development of personalized medicine launched

Alzheimer’s disease researcher joins UBC's European Scientific Advisory Board

Clinical trial of Cerebroprotein Hydrolysate for Injection completes

HTDS announces closure of Regulation D 504 offering

StemCells’ novel neuroprotective approach for treating neurodegenerative diseases

Ten of ChemBridge's screening libraries available through CDD database

PTC Therapeutics collaborates with Roche for developing bioavailable small molecules

Consortium on Neuroscience, Ethics, Legal and Social Issues

Sepracor to be acquired by Dainippon Sumitomo Pharma for $2.6 billion

NCI to announce the results of follow-up study of PharmaGap's lead drug GAP-107B8

PROTECT clinical study aimed at the assessment of rolofylline effects

Irbesartan drug minimizes heart failure complications in patients with atrial fibrillation

The biology of apoE and apoE receptors in Alzheimer's disease to be researched under new NIH program

Psychogenics and Astrazeneca sign agreement to identify new compounds for treating Central Nervous System disorders

CNS Response raises funds through private placement for general corporate purposes

Milestone reached in Biotie Wyeth collaboration for the development of PDE10 inhibitors for schizophrenia

Comprehensive review on the pharmacology of sigma receptors published in Journal of Pharmacology Therapeutics

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News